CDKN2B and cancer: Altogether, expression levels of 17 genes were altered in both RPS6KB1-suppressed and inhibitor-treated samples, including VTCN1/B7-H4, CDKN2B, SCD and ARL11. Especially, the down-regulation of VTCN1/B7-H4 is interesting, since it has recently been found to be overexpressed in a number of cancers and have also been linked to poor prognosis [21,22].